UroGen Pharma Ltd. — Director's Dealing 2021

Jun 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2021-06-07

Reporting Person: Cohen Fred E (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-07	Stock Option (right to buy)	$17.98	A	10000	Acquired	2031-06-07	Common Stock (10000)	Direct

Footnotes

F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year.